Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puretech Health Plc ADR (PRTC)

Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 404,089
  • Shares Outstanding, K 24,168
  • Annual Sales, $ 4,830 K
  • Annual Income, $ 27,780 K
  • EBIT $ 0 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.13
  • Price/Sales 83.87
  • Price/Cash Flow 7.03
  • Price/Book 1.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.01 +6.12%
on 12/05/25
18.05 -5.87%
on 12/05/25
+0.29 (+1.74%)
since 11/28/25
3-Month
15.50 +9.61%
on 11/21/25
19.23 -11.65%
on 10/02/25
-1.06 (-5.85%)
since 09/29/25
52-Week
13.30 +27.74%
on 04/10/25
20.00 -15.05%
on 04/07/25
-2.52 (-12.92%)
since 12/27/24

Most Recent Stories

More News
PureTech Appoints Robert Lyne as Chief Executive Officer

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value,...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
Leerink Partners Reaffirms Their Buy Rating on PureTech Health (PRTC)

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on PureTech Health on September 30. The company’s shares closed yesterday at $19.00.Elevate Your Investing Strategy: Take advantage of...

PRTC : 16.99 (+1.61%)
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability ...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoâ„¢ (SPT-320) in Healthy Volunteers

GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in generalized anxiety disorder (GAD) GlyphAgo is designed to overcome a key...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
PureTech Health plc – Half-Year Report

Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development ...

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)
VOR : 13.72 (-6.79%)
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

Deupirfenidone to be advanced by PureTech’s newly launched Founded Entity, Celea Therapeutics

PRTC.LN : 128.220 (+0.33%)
PRTC : 16.99 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar